Oligonucleotides: Where We Started, Where We Stand, And Where We Would Like To Go 

By Troy Voelker, Ph.D., Director of Laboratory Operations, Aliri

Dr. Voelker presented an overview of the current status and future directions of oligonucleotides (OGNTs) bioanalysis. He discussed the advantages and disadvantages of various bioanalytical techniques like LC/UV, LC/MS-MS, hybridization LC/FD, LC/HRMS, and hybridization ELISA. The right method should be chosen based on the desired detection range, sensitivity, and specificity. Dr. Voelker explains the importance of careful sample extraction and the potential issues of sample loss due to nonspecific binding properties of OGNTs or oxidation. For oligonucleotide therapeutics, hybridization-based fluorescence assays and ELISA assays can be used, each with its own benefits. Looking forward, Dr. Voelker highlighted six goals: specificity and selectivity in LC/MS extraction, simpler LC conditions, reduced multiple charge states, more bioinert consumables, increased sensitivity of mass spectrometers, and 3D spatial tissue analysis. The future of OGNTs bioanalysis will depend on the complexity and pros and cons of each analytical approach.